 |
|
 |
Oramed Pharmaceuticals (NASDAQCM:ORMP) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. Through its patented flagship product, an orally ingestible insulin capsule currently approaching Phase 2 trials under the USFDA, the Company is seeking to revolutionize the treatment of diabetes. 
|
Press Releases
May 17, 2013
Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S.
... read more »
May 1, 2013
Clinical Results for Oramed’s Oral Diabetes Treatment Published in Peer Reviewed Journal PLOS ONE ... read more »
April 29, 2013 Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013
... read more »
April 22, 2013
Oramed CEO to be Panelist at BIO International Convention Breakout Session on Israel Becoming Biotech Leader
April 18, 2013
Oramed Pharmaceuticals Chosen to Present at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna, Austria; April 18-20, 2013
... read more » |
| Press Center | Terms & Conditions | Privacy Statement | Design and programming by BIGDESIGN Creative Agency | All rights reserved © 2009 Oramed |